Regulator orders drugmaker Valeant management to cease trading
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Moody's Downgrades Valeant Pharma (VRX) to 'B2'; Ratings Remain on Review for Further Downgrade
March 31, 2016 3:08 PM EDTMoody's Investors Service downgraded certain ratings of Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and subsidiaries, including the Corporate Family Rating to B2 from B1, the Probability of Default Rating to Caa1-PD from B1-PD and the senior unsecured rating to B3 (LGD 3) from B2 (LGD 5). There is no action today on Valeant's Ba2 (LGD 2) senior secured rating, which remains under review for downgrade. All of these ratings remain under review for further downgrade, related to Valeant's late 10-K filing, continuing a rating review initiated on February 29, 2016. Moody's also affirmed Valeant's Speculative Grade... More
